Extrahepatic delivery

US12005074B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Jayaprakash K. Nair · Cambridge, US
• Martin Maier · Cambridge, US
• Vasant Jadhav · Cambridge, US
• Stuart Milstein · Cambridge, US
• Kirk Brown · Swampscott, US
• Rubina G. Parmar · Cambridge, US
• Kallanthottathil G. Rajeev · Wayland, US
• Muthiah Manoharan · Carlsbad, US
• Alexander V. Kel'in · Swampscott, US
• Muthusamy Jayaraman · Cambridge, US
• Klaus Charisse · Acton, US
• Adam Castoreno · Framingham, US
• Christopher S. THEILE · Cambridge, US
• Kevin Fitzgerald · Brookline, US

Key dates

• Filing date: May 3, 2023
• Grant date: Jun 11, 2024
• Expiry date: May 3, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

One aspect of the present invention relates to a double stranded iRNA agent comprising an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic moieties conjugated to one or more internal positions on at least one strand, optionally via a linker or carrier. Another aspect of the invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs.